X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs NOVARTIS - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES NOVARTIS DIVIS LABORATORIES/
NOVARTIS
 
P/E (TTM) x 34.7 259.0 13.4% View Chart
P/BV x 5.6 22.1 25.4% View Chart
Dividend Yield % 0.9 1.7 53.4%  

Financials

 DIVIS LABORATORIES   NOVARTIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
NOVARTIS
Mar-17
DIVIS LABORATORIES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,222855 142.9%   
Low Rs784666 117.8%   
Sales per share (Unadj.) Rs153.1219.0 69.9%  
Earnings per share (Unadj.) Rs39.919.1 209.1%  
Cash flow per share (Unadj.) Rs44.620.3 219.7%  
Dividends per share (Unadj.) Rs10.0010.00 100.0%  
Dividend yield (eoy) %1.01.3 75.8%  
Book value per share (Unadj.) Rs201.8307.0 65.7%  
Shares outstanding (eoy) m265.4729.96 886.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.63.5 188.7%   
Avg P/E ratio x25.139.8 63.1%  
P/CF ratio (eoy) x22.537.5 60.0%  
Price / Book Value ratio x5.02.5 200.7%  
Dividend payout %25.052.4 47.8%   
Avg Mkt Cap Rs m266,26622,779 1,168.9%   
No. of employees `0009.70.7 1,444.4%   
Total wages/salary Rs m4,6871,393 336.5%   
Avg. sales/employee Rs Th4,175.09,736.2 42.9%   
Avg. wages/employee Rs Th481.52,066.8 23.3%   
Avg. net profit/employee Rs Th1,089.3849.0 128.3%   
INCOME DATA
Net Sales Rs m40,6436,562 619.4%  
Other income Rs m749702 106.8%   
Total revenues Rs m41,3927,264 569.9%   
Gross profit Rs m14,460259 5,585.3%  
Depreciation Rs m1,23336 3,435.4%   
Interest Rs m237 313.9%   
Profit before tax Rs m13,953917 1,521.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349345 970.5%   
Profit after tax Rs m10,604572 1,853.2%  
Gross profit margin %35.63.9 901.8%  
Effective tax rate %24.037.6 63.8%   
Net profit margin %26.18.7 299.2%  
BALANCE SHEET DATA
Current assets Rs m40,1059,731 412.1%   
Current liabilities Rs m6,5951,830 360.3%   
Net working cap to sales %82.5120.4 68.5%  
Current ratio x6.15.3 114.4%  
Inventory Days Days11949 243.5%  
Debtors Days Days8125 320.7%  
Net fixed assets Rs m19,99557 34,956.3%   
Share capital Rs m531141 377.3%   
"Free" reserves Rs m53,0439,056 585.7%   
Net worth Rs m53,5749,196 582.6%   
Long term debt Rs m00-   
Total assets Rs m61,58511,499 535.6%  
Interest coverage x618.4128.4 481.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.6 115.6%   
Return on assets %17.35.0 342.5%  
Return on equity %19.86.2 318.1%  
Return on capital %26.110.1 259.5%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,384129 27,450.6%   
Fx outflow Rs m10,3991,734 599.7%   
Net fx Rs m24,985-1,605 -1,556.7%   
CASH FLOW
From Operations Rs m11,493-380 -3,028.5%  
From Investments Rs m-11,3724,208 -270.3%  
From Financial Activity Rs m-93-3,318 2.8%  
Net Cashflow Rs m28510 5.6%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 2.0 590.0%  
FIIs % 19.0 1.6 1,187.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 21.5 80.0%  
Shareholders   31,796 41,647 76.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SHASUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade on a Negative Note; Sensex Down Over 160 Points(12:30 pm)

After opening the day marginally higher, share markets in India witnessed selling pressure and are presently trading on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


May 21, 2018 03:35 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS